Prof. Dr. med. Markus Kosch, Head of Oncology Europe & Canada at Daiichi Sankyo on Perseverance, Patient-Centricity Beyond Slogans, and Leadership within Oncology

In this episode, I talked with Prof. Dr. med. Markus Kosch, Head of Oncology Europe and Canada at Daiichi Sankyo Europe, about what it really means to lead with empathy, perseverance, and purpose in today’s biopharma world. Markus shared how losing his father to cancer at 21 shaped his commitment to oncology — and why that experience still guides his decisions decades later.After ten years in the hospital system, he faced a turning point: realizing that to help more patients, he’d have to step outside the clinic. That leap led him into industry at a time when ADCs were still an emerging idea — and he’s since built a career around transforming long-term scientific perseverance into patient impact.Markus opened up about layoffs and restructuring, learning to lead through influence rather than authority, and why “patient-centricity” has to be more than a corporate phrase. He also shared how Daiichi Sankyo invests in nurses, why he values authenticity above experience in hiring, and how he handles tough conversations — including a live role-play on what to do when an employee asks for a promotion that isn’t possible.(Find out more in the episode.)Here’s What You’re In ForHow to lead through influence, not authorityWhat patient-centricity really looks like inside Daiichi SankyoHow perseverance and ikigai fuel innovationTimestamps03:00 – From hospital to industry — how his first pharma role came about07:15 – Leading through influence instead of authority08:10 – Guiding teams through restructuring09:45 – How empathy and transparency define good leadership12:10 – Patient-centric culture at Daiichi Sankyo17:45 – Japanese lessons in ikigai20:40 – Hiring authenticity25:00 – Role-play: handling promotion requests and career plateausAbout MarkusProf. Dr. med. Markus Kosch is Head of Oncology Europe & Canada at Daiichi Sankyo, with extensive leadership experience in oncology and global pharma. Before joining Daiichi Sankyo, he spent 16.5 years at Wyeth and Pfizer in senior roles. Trained as a physician, Markus worked for a decade treating cancer patients before moving into the pharmaceutical industry.His early personal experience with cancer — losing his father at age 21 — shaped his commitment to patient-centric innovation. Known for connecting scientific excellence with responsibility and perseverance, he focuses on advancing breakthrough oncology therapies, particularly Antibody-Drug Conjugates (ADCs). He is passionate about leadership, collaboration, and embedding patient needs at the center of every decision.Connect with MarkusLinkedIn: https://www.linkedin.com/in/markus-kosch/ Daiichi Sankyo Europe: https://www.daiichi-sankyo.eu/ About meMy name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment, I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.Connect with me:LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/ Website: https://www.discera-search.com/ Opinions and comments expressed by the guest do not represent the company and are fully their own.